Your browser is no longer supported. Please, upgrade your browser.
XLRN Acceleron Pharma Inc. daily Stock Chart
Acceleron Pharma Inc.
Index- P/E- EPS (ttm)-2.40 Insider Own0.20% Shs Outstand59.64M Perf Week5.68%
Market Cap6.99B Forward P/E- EPS next Y-2.02 Insider Trans-5.60% Shs Float52.79M Perf Month14.75%
Income-132.20M PEG- EPS next Q-0.57 Inst Own90.20% Short Float6.64% Perf Quarter28.63%
Sales106.00M P/S65.90 EPS this Y8.10% Inst Trans13.41% Short Ratio10.76 Perf Half Y28.50%
Book/sh15.01 P/B8.00 EPS next Y20.20% ROA-22.10% Target Price131.77 Perf Year141.96%
Cash/sh15.16 P/C7.92 EPS next 5Y- ROE-24.30% 52W Range46.00 - 124.01 Perf YTD126.35%
Dividend- P/FCF- EPS past 5Y-7.90% ROI-30.30% 52W High-5.84% Beta0.53
Dividend %- Quick Ratio24.50 Sales past 5Y38.30% Gross Margin- 52W Low153.85% ATR4.85
Employees237 Current Ratio24.50 Sales Q/Q438.10% Oper. Margin- RSI (14)55.80 Volatility3.66% 4.72%
OptionableYes Debt/Eq0.00 EPS Q/Q23.30% Profit Margin- Rel Volume0.68 Prev Close120.01
ShortableYes LT Debt/Eq0.00 EarningsNov 05 AMC Payout- Avg Volume326.03K Price116.77
Recom1.90 SMA202.44% SMA503.95% SMA20017.73% Volume220,201 Change-2.70%
Nov-06-20Reiterated H.C. Wainwright Buy $137 → $148
Aug-25-20Initiated Raymond James Strong Buy $155
Apr-06-20Downgrade Goldman Neutral → Sell $73
Feb-27-20Initiated Barclays Overweight $107
Feb-03-20Upgrade Morgan Stanley Equal-Weight → Overweight $122
May-29-19Resumed Goldman Neutral
May-24-19Resumed Citigroup Buy $66
May-03-19Downgrade Barclays Overweight → Equal Weight $54 → $45
Apr-22-19Resumed Oppenheimer Outperform
Feb-28-19Reiterated H.C. Wainwright Buy $72 → $67
Sep-10-18Resumed Morgan Stanley Equal-Weight $55
Jul-13-18Downgrade Morgan Stanley Overweight → Equal-Weight
Jul-10-18Downgrade Piper Jaffray Overweight → Neutral
Jun-29-18Upgrade Goldman Sell → Neutral
Feb-28-18Reiterated Barclays Overweight $50 → $54
Feb-26-18Upgrade JP Morgan Neutral → Overweight
Jan-18-18Resumed Credit Suisse Outperform $55
Nov-07-17Reiterated H.C. Wainwright Buy $57 → $62
Oct-12-17Initiated H.C. Wainwright Buy $57
Sep-15-17Initiated RBC Capital Mkts Sector Perform $44
Dec-01-20 07:00AM  
Nov-19-20 01:03PM  
Nov-16-20 11:41PM  
Nov-13-20 10:01AM  
Nov-09-20 07:00AM  
Nov-06-20 11:05AM  
Nov-05-20 06:15PM  
Nov-04-20 04:01PM  
Oct-29-20 12:34PM  
Oct-28-20 02:46PM  
Oct-26-20 04:02PM  
Sep-30-20 07:45AM  
Sep-29-20 06:59AM  
Sep-17-20 04:01PM  
Sep-16-20 07:00AM  
Sep-13-20 10:55AM  
Sep-05-20 11:31AM  
Aug-31-20 10:35PM  
Aug-26-20 10:44PM  
Aug-07-20 10:36AM  
Aug-06-20 06:15PM  
Aug-03-20 10:14AM  
Jul-30-20 12:33PM  
Jul-27-20 12:31PM  
Jul-23-20 05:12PM  
Jul-13-20 07:16PM  
Jul-11-20 05:42PM  
Jul-07-20 04:04PM  
Jul-06-20 05:01PM  
Jul-02-20 09:03AM  
Jun-30-20 06:48PM  
Jun-29-20 04:01PM  
Jun-26-20 09:05AM  
Jun-24-20 04:29PM  
Jun-22-20 07:00AM  
Jun-11-20 07:30AM  
Jun-10-20 11:30AM  
Jun-04-20 04:05PM  
Jun-01-20 02:58PM  
May-20-20 07:00AM  
May-19-20 07:00AM  
May-13-20 04:01PM  
May-12-20 04:31PM  
May-11-20 05:45PM  
May-05-20 07:00AM  
May-04-20 07:00AM  
May-02-20 04:32PM  
Apr-30-20 04:16PM  
Apr-24-20 11:41AM  
Apr-21-20 05:31PM  
Apr-09-20 02:24PM  
Apr-08-20 02:38PM  
Apr-07-20 04:05PM  
Apr-06-20 10:03PM  
Apr-03-20 05:08PM  
Mar-29-20 07:38PM  
Mar-26-20 06:59AM  
Mar-09-20 04:05PM  
Mar-04-20 08:15AM  
Feb-27-20 05:35PM  
Feb-26-20 08:49AM  
Feb-20-20 04:10PM  
Feb-19-20 07:59AM  
Feb-18-20 10:46AM  
Feb-03-20 10:18AM  
Jan-29-20 09:59AM  
Jan-28-20 04:22PM  
Jan-27-20 06:06PM  
Jan-23-20 04:15PM  
Jan-13-20 06:13PM  
Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers luspatercept-aamt for the treatment of anemia in adult patients with beta-thalassemia under the REBLOZYL name. The company also develops luspatercept-aamt for the treatment of myelodysplastic syndromes and myelofibrosis; Sotatercept for the treatment of patients with pulmonary arterial hypertension; and ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with Charcot-Marie-Tooth disease. In addition, it has a collaboration, license, and option agreement with Celgene Corporation; and collaboration and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kearney Terrence CDirectorOct 12Option Exercise28.6237,5001,073,37542,627Oct 13 07:14 PM
Kearney Terrence CDirectorOct 12Sale119.3637,5004,475,9815,127Oct 13 07:14 PM
MCCOURT Thomas ADirectorSep 11Option Exercise32.5823,272758,31627,694Sep 15 04:51 PM
MCCOURT Thomas ADirectorSep 11Sale90.3923,2722,103,4664,422Sep 15 04:51 PM
Veness Adam MSVP, General Counsel and Sec.Sep 08Sale89.502,000179,00419,161Sep 09 05:49 PM
CELGENE CORP /DE/10% OwnerJul 09Sale102.282,241229,2097,008,510Jul 13 06:27 PM
Dable Habib JCEO and PresidentJul 01Option Exercise35.0450,0001,752,000139,324Jul 06 06:57 PM
CELGENE CORP /DE/10% OwnerJul 01Buy92.50108,1089,999,9906,971,772Jul 06 05:24 PM
Dable Habib JCEO and PresidentJul 01Sale96.4150,0004,820,44589,324Jul 06 06:57 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerApr 09Option Exercise41.2017,226709,71128,442Apr 10 05:29 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerApr 09Sale88.1917,2261,519,16111,216Apr 10 05:29 PM
Veness Adam MSVP, General Counsel and Sec.Apr 08Option Exercise27.976,000167,82027,161Apr 10 05:30 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerApr 08Option Exercise32.7436,7741,204,12947,990Apr 10 05:29 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerApr 08Sale85.5136,7743,144,61411,216Apr 10 05:29 PM
Veness Adam MSVP, General Counsel and Sec.Apr 08Sale85.586,000513,50921,161Apr 10 05:30 PM
Zakrzewski Joseph SDirectorJan 07Option Exercise3.8818,75072,75031,500Jan 09 04:36 PM
KANGO SUJAYSVP, Chief Commercial OfficerJan 03Sale51.3748024,6579,570Jan 03 09:48 PM
Dable Habib JCEO and PresidentJan 03Sale51.243,732191,23067,151Jan 03 09:37 PM
Veness Adam MVP, General Counsel and Sec.Jan 03Sale51.2387544,82614,792Jan 03 09:51 PM
Veness Adam MVP, General Counsel and Sec.Jan 02Sale52.8343422,92815,667Jan 03 09:51 PM
Quisel John DEVP, Chief Business OfficerJan 02Sale52.525,842306,80653,316Jan 03 09:45 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerJan 02Sale52.505,579292,9234,847Jan 03 09:41 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerDec 13Sale50.2811,853595,96910,426Dec 17 06:39 PM